Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals

Ana Lleo, Andrea Aglitti, Alessio Aghemo, Patrick Maisonneuve, Savino Bruno, Marcello Persico, Maria Rendina, Alessia Ciancio, Pietro Lampertico, Maurizia R. Brunetto, Vito Di Marco, Massimo Zuin, Pietro Andreone, Erica Villa, Giulia Troshina, Elisabetta Degasperi, Barbara Coco, Vincenza Calvaruso, Alessia M. Giorgini, Fabio ContiAlfredo Di Leo, Luca Marzi, Vincenzo Boccaccio, Simona Bollani, Massimo Colombo

Research output: Contribution to journalArticle

Abstract

Background: Despite the dramatic improvement in viral eradication rates that has been reached with direct antiviral agents (DAAs), the real benefit of viral eradication after DAAs on hepatocellular carcinoma (HCC) development is still controversial. Aim: To prospectively assess the risk of HCC occurrence and early recurrence in a large cohort of DAA-treated HCV-cirrhotic patients and to identify potential predictors of HCC development. Methods: We analyzed data prospectively collected from 1927 consecutive HCV-infected cirrhotic patients treated with DAA from January to December 2015 in 10 tertiary liver centers in Italy and followed-up for one year after therapy. 161 patients had a previous HCC. Results: 38/161 subjects developed tumor recurrence during the follow-up (recurrence rate = 24.8 per 100-year), patients with SVR had a significantly lower rate of recurrence. Lack of SVR and alpha-fetoprotein (AFP) were independent predictors of HCC recurrence. 50/1766 patients without a previous HCC history developed HCC during follow-up (incidence rate = 2.4 per 100-year). Lack of SVR was the strongest predictor of HCC development. Furthermore, patients with SVR and no stigmata of portal hypertension have a lower incidence rate of HCC (1.0 per 100-year). Conclusions: SVR is associated with a significant decrease of recurrent or de novo HCC. Baseline AFP and signs of portal hypertension can help to stratify the risk of HCC.

Original languageEnglish
Pages (from-to)310-317
JournalDigestive and Liver Disease
Volume51
Issue number2
DOIs
Publication statusPublished - 2019

    Fingerprint

Keywords

  • Cirrhosis
  • Direct antiviral agents
  • HCV
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Lleo, A., Aglitti, A., Aghemo, A., Maisonneuve, P., Bruno, S., Persico, M., Rendina, M., Ciancio, A., Lampertico, P., Brunetto, M. R., Di Marco, V., Zuin, M., Andreone, P., Villa, E., Troshina, G., Degasperi, E., Coco, B., Calvaruso, V., Giorgini, A. M., ... Colombo, M. (2019). Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. Digestive and Liver Disease, 51(2), 310-317. https://doi.org/10.1016/j.dld.2018.10.014